In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O).
Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax...
Similarities can be seen in red,yellow,green
The breakabove the fib circle level, which has previously been seen as a strong resistance point is an extremely good sign
along with the possible development of a vaccine for a new variant (if the current vaccine isn't effective)
NVAX looks bullish